New Dual-Action antibody takes on advanced tumors

NCT ID NCT05767060

Completed Disease control Sponsor: Bio-Thera Solutions Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called BAT7104 in 86 people with advanced cancers that had stopped responding to standard treatments. The drug is a bispecific antibody designed to block two proteins (PD-L1 and CD47) that help tumors hide from the immune system. The main goals were to check safety and find the right dose, while also looking for any signs that the tumors might shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAT7104 injection (a bispecific antibody targeting PD-L1 and CD47)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMOR

Contacts and locations

Locations

Li Zhang

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.